1
|
Oliveira AP, Silva AL, Viana LG, Silva MG, Lavor ÉM, Oliveira-Júnior RG, Alencar-Filho EB, Lima RS, Mendes RL, Rolim LA, Anjos DS, Ferraz LR, Rolim-Neto PJ, Silva MF, Pessoa CDÓ, Almeida JR. β-Cyclodextrin complex improves the bioavailability and antitumor potential of cirsiliol, a flavone isolated from Leonotis nepetifolia (Lamiaceae). Heliyon 2019; 5:e01692. [PMID: 31720439 PMCID: PMC6838880 DOI: 10.1016/j.heliyon.2019.e01692] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 04/14/2019] [Accepted: 05/07/2019] [Indexed: 02/08/2023] Open
Abstract
Cirsiliol is a flavone found in many Lamiaceae species with high cytotoxic activity against tumor cell lines. Although cirsiliol is being used in cancer therapy, its pharmacological potential is limited by its low solubility and bioavailability. In this paper, a cirsiliol-β-cyclodextrin inclusion complex was developed in order to increase its solubility and bioavailability. The formation of inclusion complex was proved by scanning electron microscopy, Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) and solubility increment was verified through the ultraviolet-visible (UV-Vis) method. The cytotoxic effect against tumor cells (PC3, HCT-116 and HL-60 human cell lines, and S-180 murine cell line) and the antitumor activity in mice bearing sarcoma S-180 were also investigated. The inclusion complex was obtained with 71.45% of total recovery and solubility 2.1 times higher compared to the compound in its free form. This increment in solubility was responsible by a tumor growth inhibition potentiation (1.5 times greater compared to compound in its free form). In addition, this study showed that cirsiliol and its inclusion complex in β-cyclodextrin have strong antitumor potential at low doses without promoting side effects commonly observed for conventional drugs as doxorubicin.
Collapse
Affiliation(s)
- Ana P. Oliveira
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
- Post-Graduate Program in Biotechnology (RENORBIO), Recife, Pernambuco, CEP 52.171-900, Brazil
| | - Andressa L.N. Silva
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
| | - Lucas G.F.C. Viana
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
| | - Mariana G. Silva
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
- Post-Graduate Program in Biotechnology (RENORBIO), Recife, Pernambuco, CEP 52.171-900, Brazil
| | - Érica M. Lavor
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
- Post-Graduate Program in Biotechnology (RENORBIO), Recife, Pernambuco, CEP 52.171-900, Brazil
| | - Raimundo G. Oliveira-Júnior
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
| | - Edilson B. Alencar-Filho
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
| | - Ricardo S. Lima
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
| | - Rosemairy L. Mendes
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
| | - Larissa A. Rolim
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
- Post-Graduate Program in Biotechnology (RENORBIO), Recife, Pernambuco, CEP 52.171-900, Brazil
| | - Débora S.C. Anjos
- Federal Institute of Science and Technology of Sertão Pernambucano, Petrolina, Pernambuco, CEP 56316-686, Brazil
| | - Leslie R.M. Ferraz
- Federal University of Pernambuco, Recife, Pernambuco, CEP 50.670-901, Brazil
| | - Pedro J. Rolim-Neto
- Federal University of Pernambuco, Recife, Pernambuco, CEP 50.670-901, Brazil
| | - Maria F.S. Silva
- Federal University of Ceará, Fortaleza, Ceará, CEP 60.020-181, Brazil
| | | | - Jackson R.G.S. Almeida
- Center for Studies and Research of Medicinal Plants (NEPLAME), Federal University of San Francisco Valley, Petrolina, Pernambuco, CEP 56.304-917, Brazil
- Post-Graduate Program in Biotechnology (RENORBIO), Recife, Pernambuco, CEP 52.171-900, Brazil
| |
Collapse
|
2
|
Mohammed-Saeid W, Karoyo AH, Verrall RE, Wilson LD, Badea I. Inclusion Complexes of Melphalan with Gemini-Conjugated β-Cyclodextrin: Physicochemical Properties and Chemotherapeutic Efficacy in In-Vitro Tumor Models. Pharmaceutics 2019; 11:pharmaceutics11090427. [PMID: 31443452 PMCID: PMC6781286 DOI: 10.3390/pharmaceutics11090427] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 08/06/2019] [Accepted: 08/10/2019] [Indexed: 11/16/2022] Open
Abstract
β-cyclodextrin (βCD) has been widely explored as an excipient for pharmaceuticals and nutraceuticals as it forms stable host–guest inclusion complexes and enhances the solubility of poorly soluble active agents. To enhance intracellular drug delivery, βCD was chemically conjugated to an 18-carbon chain cationic gemini surfactant which undergoes self-assembly to form nanoscale complexes. The novel gemini surfactant-modified βCD carrier host (hereafter referred to as 18:1βCDg) was designed to combine the solubilization and encapsulation capacity of the βCD macrocycle and the cell-penetrating ability of the gemini surfactant conjugate. Melphalan (Mel), a chemotherapeutic agent for melanoma, was selected as a model for a poorly soluble drug. Characterization of the 18:1βCDg-Mel host–guest complex was carried out using 1D/2D 1H NMR spectroscopy and dynamic light scattering (DLS). The 1D/2D NMR spectral results indicated the formation of stable and well-defined 18:1βCDg-Mel inclusion complexes at the 2:1 host–guest mole ratio; whereas, host–drug interaction was attenuated at greater 18:1βCDg mole ratio due to hydrophobic aggregation that accounts for the reduced Mel solubility. The in vitro evaluations were performed using monolayer, 3D spheroid, and Mel-resistant melanoma cell lines. The 18:1βCDg-Mel complex showed significant enhancement in the chemotherapeutic efficacy of Mel with 2–3-fold decrease in Mel half maximal inhibitory concentration (IC50) values. The findings demonstrate the potential applicability of the 18:1βCDg delivery system as a safe and efficient carrier for a poorly soluble chemotherapeutic in melanoma therapy.
Collapse
Affiliation(s)
- Waleed Mohammed-Saeid
- Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada
- College of Pharmacy, Taibah University, Medina 42353, Saudi Arabia
| | - Abdalla H Karoyo
- Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, SK S7N 5C9, Canada
| | - Ronald E Verrall
- Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, SK S7N 5C9, Canada
| | - Lee D Wilson
- Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, SK S7N 5C9, Canada
| | - Ildiko Badea
- Drug Discovery and Development Research Group, College of Pharmacy and Nutrition, University of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.
| |
Collapse
|
3
|
Liu Z, Huang P, Law S, Tian H, Leung W, Xu C. Preventive Effect of Curcumin Against Chemotherapy-Induced Side-Effects. Front Pharmacol 2018; 9:1374. [PMID: 30538634 PMCID: PMC6277549 DOI: 10.3389/fphar.2018.01374] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2018] [Accepted: 11/08/2018] [Indexed: 12/29/2022] Open
Abstract
Cancer is still a severe threat to the health of people worldwide. Chemotherapy is one of main therapeutic approaches to combat cancer. However, chemotherapy only has a limited success with severe side effects, especially causing damage to normal tissues such as bone marrow, gastrointestine, heart, liver, renal, neuron, and auditory tissues, etc. The side-effects limit clinical outcome of chemotherapy and lower patients’ quality of life, and even make many patients discontinue the chemotherapy. Thus, there is a need to explore effective adjuvant strategies to prevent and reduce the chemotherapy-induced side effects. Naturally occurring products provide a rich source for exploring effective adjuvant agents to prevent and reduce the side effects in anticancer chemotherapy. Curcumin is an active compound from natural plant Curcuma longa L., which is widely used as a coloring and flavoring agent in food industry and a herbal medicine in Asian countries for thousands of years to treat vomiting, headache, diarrhea, etc. Modern pharmacological studies have revealed that curcumin has strong antioxidative, anti-microbial, anti-inflammatory and anticancer activities. Growing evidence shows that curcumin is able to prevent carcinogenesis, sensitize cancer cells to chemotherapy, and protect normal cells from chemotherapy-induced damages. In the present article, we review the preventive effect of curcumin against chemotherapy-induced myelosuppression, gastrointestinal toxicity, cardiotoxicity, hepatotoxicity, nephrotoxicity, neurotoxicity, ototoxicity, and genotoxicity, and discuss its action mechanisms.
Collapse
Affiliation(s)
- Zhijun Liu
- Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
| | - Pengyun Huang
- Faculty of Medicine, School of Chinese Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.,Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, Shenzhen, China
| | - Siukan Law
- Faculty of Medicine, School of Chinese Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.,Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, Shenzhen, China
| | - Haiyan Tian
- Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou, China
| | - Wingnang Leung
- Division of Chinese Medicine, School of Professional and Continuing Education, The University of Hong Kong, Pokfulam, Hong Kong
| | - Chuanshan Xu
- Key Laboratory of Molecular Target and Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.,Faculty of Medicine, School of Chinese Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.,Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, Shenzhen, China
| |
Collapse
|
4
|
Michel D, Mohammed-Saeid W, Getson H, Roy C, Poorghorban M, Chitanda JM, Verrall R, Badea I. Evaluation of β-cyclodextrin-modified gemini surfactant-based delivery systems in melanoma models. Int J Nanomedicine 2016; 11:6703-6712. [PMID: 28003746 PMCID: PMC5161338 DOI: 10.2147/ijn.s121156] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Novel drug delivery systems are developed to improve the biological behavior of poorly soluble drugs and to improve therapeutic outcomes. In melanoma therapy, the goal is efficient drug delivery and mitigation of drug resistance. Melphalan (Mel), a currently used therapeutic agent for melanoma, requires solvent system for solubilization, leading to poor chemical stability. Moreover, drug resistance often renders the drug inefficient in clinical setting. A novel β-cyclodextrin-modified gemini surfactant (CDgemini) delivery system was developed to incorporate Mel in order to improve its physicochemical and biological behavior. Melphalan nanoparticles (Mel-NP) showed optimal particle size in the 200-250 nm range for endocytosis and induced significantly higher cell death compared with Mel (50% of inhibitory concentration [IC50] of 36 µM for the complexes vs 82 µM for Mel). The CDgemini delivery system did not alter the pathway of the cellular death triggered by Mel and caused no intrinsic toxicity to the cells. The Mel-NP complexes induced significant cell death in melanoma cells that were rendered resistant to Mel. These findings demonstrate in principle the applicability of the CDgemini delivery system as safe and efficient alternative to the current melanoma therapy, especially in chemoresistant cases.
Collapse
Affiliation(s)
- Deborah Michel
- Drug Design and Discovery Research Group, College of Pharmacy and Nutrition
| | | | - Heather Getson
- Drug Design and Discovery Research Group, College of Pharmacy and Nutrition
| | - Caitlin Roy
- Drug Design and Discovery Research Group, College of Pharmacy and Nutrition
| | | | - Jackson M Chitanda
- Department of Chemistry, University of Saskatchewan, Saskatoon, SK, Canada
| | - Ronald Verrall
- Department of Chemistry, University of Saskatchewan, Saskatoon, SK, Canada
| | - Ildiko Badea
- Drug Design and Discovery Research Group, College of Pharmacy and Nutrition
| |
Collapse
|